COVID:19: How Will Delays in Vaccine Rollouts Affect the Economy?


  • According to a new report by the McKell Institute, delays in delivering the COVID-19 vaccine will cost the economy AU$1.4 billion.
  • Israel has had the fastest vaccine rollout globally, with 55.1% of its population having received both doses of the Pfizer vaccine.
  • Australia will need to increase its rate of vaccination delivery by 11.6-15 times its current rate to meet existing targets set out by the federal government.

Delays in the COVID-19 vaccine rollout may put extra weight on the Australian economy, with the current rate not matching the initial plan set out by the federal government, which set out to vaccinate 4 million people by the end of March.

A report by The McKell Institute has found that Australia will have to increase the vaccinate rate by 11.6-15 times from the current level to meet the targets set out in the federal government’s Roadmap.

In January, Prime Minister Scott Morrison stated that 4 million doses would be administered by the end of March 2021. This was later revised to 4 million doses to be administered by the end of April 2021.

According to The Department of Health, by the end of March, approximately 507,000 doses had been administered as part of the Phase 1 rollout.

This means that Australia requires the second-fastest vaccination program per capita to meet existing Roadmap targets.

ALSO READ: Australia restricts AstraZeneca’s vaccine rollout, to get third COVID-19 vaccine shortly

Source: © Mikemareen|

Israel Leading the Way

Currently, Israel has the fastest vaccination rate, with 55.1% of the population having been vaccinated (114.4 doses administered per 100 people). This has resulted in Israel being largely reopened as restrictions have eased for those who have received both doses of the Pfizer vaccine.

Moreover, Israeli vaccination efforts have proven encouraging, as an Israeli study found that those who have received the first dose of the Pfizer (NYSE:PFE) vaccine may reduce viral loads in the subject, thus making it more difficult to transmit COVID-19 if that subject becomes infected after the first dose.

Under the current Australian Roadmap, the first dose of the COVID-19 vaccine is due for completion in October 2021, with the second dose due for completion in November or December, pending supply.

DO READ: Are the Vaccines Working? When will Covid-19 end?

The Cost of Delays

The costs associated with the current delays in administering the vaccine are likely to reach nearly AU$1.4 billion, according to the McKell Institute report, Counting the Cost of Australian’s Delayed Vaccination Roll-out.

Source: © Kovop58 |

Even if Australia increases its vaccination rollout rate to the second-fastest in the world – currently held by the UK – it would delay herd immunity by 116 days from the government’s original projection, which would result in an extra 11.1 days of lockdown, costing the economy an additional AU$1.368 billion. Furthermore, delayed immunity also will likely result in increased border lockdowns, which will also add to the cost.

GOOD READ: COVID-19 Weekly Roundup: Latest developments around the world

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK